HIV Vaccines in the News

Quick Links: HVTN 505 | Thailand's HIV Vaccine Trial | Other HIV Vaccine News

Date: July 11, 2013
Title: An AIDS-free generation is closer than we might think
Source: The Washington Post
Summary: Because of the extraordinary progress in the fight against HIV/AIDS, we can now consider a question that just a few years ago seemed far-fetched. No longer is it whether we can achieve an AIDS-free generation. Now, the question is: How long will it take and will it be sustained?
Date: June 12, 2013
Title: New PrEP Trial Results Among Injecting Drug Users Underscore That PrEP Works When Taken Consistently; AVAC Calls for Accelerated Action to Get PrEP to Those Who Can Benefit From It.
Source: AVAC
Summary: Results from the Bangkok Tenofovir Study published online today in The Lancet provide additional evidence that daily oral tenofovir-based pre-exposure prophylaxis (PrEP) reduces HIV infection risk when taken consistently.
Date: June 12, 2013
Title: Gilead's Viread Reduces HIV Risk for Drug Users in Study
Source: Bloomberg
Summary: Gilead Sciences Inc. (GILD)'s Viread pill reduced the risk of injected-drug users contracting the AIDS virus by half in a study in Thailand, a finding that may give public health officials a new weapon to fight HIV's spread.
Date: June 12, 2013
Title: Gilead's Viread Reduces HIV Risk for Drug Users in Study
Source: Bloomberg
Summary: Gilead Sciences Inc. (GILD)'s Viread pill reduced the risk of injected-drug users contracting the AIDS virus by half in a study in Thailand, a finding that may give public health officials a new weapon to fight HIV's spread.
›› Information About HVTN 505

HVTN 505 Study Flyer
Questions and Answers: The HVTN 505 Vaccine Trial
Preguntas y respuestas: Ensayo de vacuna HVTN 505

›› News About HVTN 505
Date: May 17, 2013
Title: Moving forward on HIV Vaccine Awareness Day
Summary:Some of the world’s brightest minds have been on this quest for 30 years, yet we still do not have an HIV vaccine to use today. Recent clinical trials, such as the HVTN 505 study that was stopped because the vaccine was shown to be ineffective at preventing HIV, have generated new challenges to the field.
Date: May 16, 2013
Title: The Search Must Continue: Halted HIV-vaccine trial may be a setback, but it's not a defeat
Source: Metro Weekly
Summary: An AIDS vaccine remains critical to a long-term strategy to end the AIDS epidemic in my community and around the world. It's important to remember that our battle against HIV has never been easy.
Date: April 25, 2013
Title: NIH Discontinues Immunizations in HIV Vaccine Study
Source: NIAID
Summary: The world's largest ongoing HIV vaccine study is changing the scope of its primary goals to include an investigation of whether the experimental vaccine regimen prevents HIV infection.
Date: Aug 4, 2011
Title: HVTN 505 HIV Vaccine Study to Expand Scope
Source: NIAID
Summary: Scheduled interim review of DSMB finds vaccine regimen did not prevent HIV infection nor reduce viral load among vaccine recipients.
Date: Aug 4, 2011
Title: HVTN 505 HIV Vaccine Study to Expand Scope
Source: NIAID
Summary: The world's largest ongoing HIV vaccine study is changing the scope of its primary goals to include an investigation of whether the experimental vaccine regimen prevents HIV infection.
Date: Oct 1, 2009
Title: New trial of HIV vaccine in gay men begins
Source: Bay Area Reporter
Summary: AIDS researchers have begun recruiting gay men in various American cities for a new HIV vaccine trial.
Date: Sep 30, 2009
Title: Group looks for vaccine-study candidates
Source: Windy City Times
Summary: Project WISH, a research group that operates out of the University of Illinois at Chicago Medical Center, has announced that they are actively searching for candidates to participate in a new HIV vaccine study that will begin testing shortly.
Date: Sep 17, 2009
Title: New HIV/AIDS vaccine study seeks volunteers
Source: The Edge
Summary: Edge article on HVTN 505 provides insight from San Francisco volunteer on importance of the search for HIV vaccine.
Date: Aug 24, 2009
Title: HVTN 505 HIV Vaccine Study Begins Enrolling Volunteers
Source: NIAID
Summary: The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, has opened enrollment in HVTN 505, an exploratory HIV vaccine clinical study examining whether a two-part vaccine regimen can decrease viral load (the amount of HIV in the blood) in study participants who later become infected with HIV.

›› News About Thailand's HIV Vaccine Trial of RV144
Date: Oct 20, 2009
Title: AIDS Vaccine Study Reassures Skepticsbr> Source: Science
Summary: After a thorough examination of data, scientists skeptical about the Thai vaccue trial believe the vaccine does offer modest HIV protection.
Date: Oct 12, 2009
Title: Spotlight: AIDS Vaccine
Source: Time
Summary: After a two-decade drought of good news, AIDS-vaccine researchers are finally dancing under the first raindrops of hope. It's not a downpour by any means or even a soaking shower, but it's something. At the end of a six-year vaccine field trial—the largest ever conducted—scientists have their first successful immunization against HIV.
Date: Oct 5, 2009
Title: An AIDS Vaccine is Now More than a Dream
Source: Huffington Post
Summary: Mitchell Warren, Executive Director of AVAC writes that "the elusive dream of an AIDS vaccine is one step closer to reality."
Date: Oct 1, 2009
Title: HIV vaccine stems from UR foundation
Source: Campus Times (University of Rochester)
Summary: Preliminary studies that led to the development of the vaccine used in the Thailand trial were performed at University of Rochester in the late 1990s.
Date: Sep 24, 2009
Title: The Quest for an HIV Vaccine
Source: XConomy Seattle
Summary: An article by HVTN director Lawrence Corey, underscoring the significance of the Thai vaccine trial.
Date: Sep 24, 2009
Title: For First Time, AIDS Vaccine Shows Some Success
Source: New York Times
Summary: A vaccine tested in 16,000 people in Thailand showed a 31.2% success rate in preventing HIV infection. This is not enough to license the vaccine, but the study energizes the field of HIV vaccine research.
Date: Sep 24, 2009
Title: A statement by Larry Corey, M.D., on the success of the HIV Vaccine Trial in Thailand
Source: HIV Vaccine Trials Network
Summary: The HIV Vaccine Trials Network congratulates the consortium of partners that led the trial, especially the Thai Ministry of Health and the U.S. Military HIV Research Program.
Date: Sep 24, 2009
Title: Global HIV Vaccine Enterprise Hails Significant Results from HIV Vaccine Study in Thailand
Source: Global HIV Vaccine Enterprise
Summary: A statement by Alan Bernstein, executive director of the Global HIV Vaccine Enterprise. "This is a historic day in the 26-year quest to develop an AIDS vaccine."
Date: Sep 24, 2009
Title: RV144 Phase III HIV Vaccine Trial Press Release
Source: U.S. Military HIV Research Program
Summary: A Phase III clinical trial involving more than 16,000 adult volunteers in Thailand has demonstrated that an investigational HIV vaccine regimen was safe and modestly effective in preventing HIV infection.

Date: Spring 2010
Title: Wait, Wait, Don't Test Me!
Source: HIV Specialist
Summary: Special considerations when testing HIV vaccine trial volunteers. By Steven Wakefield and Sarah Alexander of the HIV Vaccine Trials Network.
Date: January 27, 2010
Title: The Earthquake in Haiti — Dispatch from Port-au-Prince
Source: The New England Journal of Medicine
Summary: A report from Dr. Jean Pape, Principal Investigator at GHESKIO, an HVTN site in Haiti.
Date: November 2, 2009
Title: Two Videos about the Seattle HIV Vaccine Trials Unit
Source: KOMO4 News   Video 1 | Video 2
Summary: KOMO4 News visits Seattle HIV Vaccine Trials Unit, a program of the Fred Hutchinson Cancer Research Center, which is enrolling participants for HIV vaccine research.
Date: Summer 2009
Title: The Nation's Top HIV/AIDS Researcher Discusses This Continuing Health Threat
Source: Medline Plus
Summary: For the past three decades, Dr. Anthony S. Fauci, Director of the National Institute of Allergy and Infectious Diseases (NIAID), has overseen extensive research efforts to prevent, diagnose, and treat infectious diseases, such as HIV/AIDS and other sexually transmitted infections, influenza, tuberculosis, malaria, and illness from potential agents of bioterrorism. In this article, he speaks about the continuing challenge of HIV/AIDS.
Date: July 31, 2009
Title: Monitoring HIV vaccine trial participants for primary infection: studies in the SIV/macaque model
Source: AIDS
Summary: The ability to detect and quantify acute HIV-1 infection prior to seroconversion would be an important tool for use in HIV vaccine clinical efficacy trials. We have utilized the SIV/rhesus monkey model to evaluate whether samples more easily obtained than peripheral blood might be used for intensive monitoring of vaccine trial participants.
Date: July 23, 2009
Title: An ill wind for wild chimps?
Source: Nature
Summary: Simian immunodeficiency virus is associated with increased mortality in a subspecies of chimpanzee living under natural conditions in East Africa. Until now, it has been widely assumed that the precursor of HIV-1, chimpanzee simian immunodeficiency virus (SIVcpz), causes little, if any, illness in its animal host.
Date: July 23, 2009
Title: A Look at Seattle's HIV Vaccine Trials Unit
Source: KBCS 91.3 FM
Summary: Our world is home to 36 million people living with HIV. And 16,000 more people become infected every day. AIDS, the syndrome caused by HIV, has no cure. Treatment costs as much as the average American earns, and can cause debilitating side effects. This radio program features members of Seattle's HIV Vaccine Trials Unit.
Dates: Various
Title: HIV/AIDS Supplement
Source: Nature
Summary: This special collection of papers on HIV/AIDS published in Nature highlights the progress that has been made towards conquering this enormous challenge over the past couple of years.
Date: July 20, 2009
Title: Vaccine trial a 'giant leap'
Summary: The first clinical trial of an HIV/AIDS vaccine designed and developed in South Africa was launched in Cape Town.
Date: July 15, 2009
Title: Fenway and the MAC launch study on black gay men and HIV
Summary: A new study aims at learning more about the sexual health of black gay and bi men and finding effective strategies for HIV prevention within the black gay community.
Date: Nov 13, 2008
Title: Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial
Source: The Lancet
Summary: Observational data and non-human primate challenge studies suggest that cell-mediated immune responses might provide control of HIV replication. The Step Study directly assessed the efficacy of a cell-mediated immunity vaccine to protect against HIV-1 infection or change in early plasma HIV-1 levels. Authors: Susan P Buchbinder, Devan V Mehrotra, Ann Duerr, Daniel W Fitzgerald, Robin Mogg, David Li, Peter B Gilbert, Javier R Lama, Michael Marmor, Carlos del Rio, M Juliana McElrath, Danilo R Casimiro, Keith M Gottesdiener, Jeffrey A Chodakewitz, Lawrence Corey, Michael N Robertson. Published in The Lancet.
Date: Oct 13, 2008
Title: Larry Corey elected to Institute of Medicine
Source: The Lancet
Summary: Dr. Larry Corey, senior vice president and co-director of the Center’s Vaccine and Infectious Disease Institute, was named as one of 65 new members of the prestigious Institute of Medicine.
Date: Aug 22, 2008
Title: Examining future lessons of HIV vaccine trials
Source: Miramichi Leader
Summary: Interview with Dr. Bhagirath Singh, Scientific Director of the Canadian Institutes of Health Research Institute of Infection and Immunity, who shares his thoughts on the need to recommit to the crusade to find a vaccine for HIV/AIDS.
Date: June 11, 2008
Title: Examining future lessons of HIV vaccine trials
Summary: Researchers in Los Angeles map the common barriers between participants' willingness to participate in vaccine trials and the acceptability of a hypothetical vaccine.
Date: May 8, 2008
Title: A STEP into Darkness or Light?
Source: Science
Summary: The recent failure of a vector-based HIV vaccine may be explained by individual subjects' immune capacity and genetics.
Date: May 8, 2008
Title: AIDS and the Next 25 Years
Source: Science
Summary: Alan Bernstein, executive director of the Global HIV Vaccine Enterprise emphasizes the need for more research.
Date: May 8, 2008
Title: Toward an AIDS Vaccine
Source: Science
Summary: The goal of developing an AIDS vaccine remains elusive. However, evidence of protection against AIDS viruses in animal models and control of HIV in humans under certain circumstances, together with scientific advances in understanding disease pathogenesis, provide a strong rationale and objective paths to continue the pursuit of an effective AIDS vaccine.
Date: May 8, 2008
Title: Reassessing HIV Prevention
Source: Science
Summary: The largest investments in AIDS prevention targeted to the general population are being made in interventions where the evidence for large-scale impact is uncertain.
Date: April 25, 2008
Title: We Are Making Progress on AIDS
Source: Wall Street Journal
Summary: IAVI CEO Seth Berkley presents scientific reasons to believe we can create a vaccine against AIDS.
Date: April 21, 2008
Title: In Search of an AIDS Vaccine: Rededication follows disappointment
Source: Wall Street Journal
Summary: Finding a vaccine is neither easy nor fast, however, and failure of human vaccine trials is common. There's still much that isn't known about the virus or AIDS. So what might look like a devastating failure to the public could be a steppingstone to advanced medications and an eventual cure.
Date: January 14, 2008
Title: Researchers Find Cell Protein That Nips HIV In The Bud
Source: Medical News Today
Summary: UCLA researchers have found that a key protein in the body's dendritic cells can stop the virus that causes AIDS from "budding" part of the virus' life cycle that is crucial to its ability to replicate and infect other cells.
Date: January 10, 2008
Title: HIV-1 Broadly Neutralizing Antibody Extracts Its Epitope from a Kinked gp41 Ectodomain Region on the Viral Membrane
Source: Immunity
Summary: Although rarely elicited during natural human infection, the most broadly neutralizing antibodies (BNAbs) against diverse human immunodeficiency virus (HIV)-1 strains target the membrane-proximal ectodomain region (MPER) of viral gp41. To gain insight into MPER antigenicity, immunogenicity, and viral function, we studied its structure in the lipid environment by a combination of nuclear magnetic resonance (NMR), electron paramagnetic resonance (EPR), and surface plasmon resonance (SPR) techniques. The analyses revealed a tilted N-terminal ? helix (aa 664–672) connected via a short hinge to a flat C-terminal helical segment (675–683). This metastable L-shaped structure is immersed in viral membrane and, therefore, less accessible to immune attack. Nonetheless, the 4E10 BNAb extracts buried W672 and F673 after initial encounter with the surface-embedded MPER. The data suggest how BNAbs may perturb tryptophan residue-associated viral fusion involving the mobile N-terminal MPER segment and, given conservation of MPER sequences in HIV-1, HIV-2, and SIV, have important implications for structure-guided vaccine design.
Date: January 6, 2008
Title: HIV Isolate From Kenya Provides Clues For Vaccine Design
Source: Science Daily
Summary: Two simple changes in its outer envelope protein could render the AIDS virus vulnerable to attack by the immune system, according to research from Kenya and the Fred Hutchinson Cancer Research Center. The results could provide important clues for designing an effective AIDS vaccine.
Date: December 27, 2007
Title: One Step Forward, Two Steps Back — Will There Ever Be an AIDS Vaccine?
Source: New England Journal of Medicine
Summary: About a quarter-century after the discovery of HIV, there is neither a marketable vaccine nor a credible expectation about when there will be one.
Date: December 18, 2007
Title: A Shot at Stopping AIDS
Source: Washington Post
Summary: Editorial by Seth Berkley, chief executive and president of the International AIDS Vaccine Initiative. Despite some setbacks, there are good reasons to think we can win against AIDS. The failure of one vaccine product does not rule out success on that front.
Date: November 12, 2007
Title: Finding the way again after failed AIDS vaccine
Source: MSNBC
Summary: The vaccine development world is now in a state of stunned shock since the trial that many believed had the greatest chance of success was halted. So what should be done next? Clearly many scientists must carry out as many experiments as possible to understand the STEP results. Dr. Seth Berkley, head of the International AIDS Vaccine Initiative, emphasizes the race to find a vaccine is a “marathon not a sprint” and we should not lose sight of the goal.
Date: November 12, 2007
Title: Fallout from failed AIDS vaccine could dampen research
Source: Forbes
Summary: Experts are concerned that the news of the Step Study will keep would-be trial participants away from future AIDS vaccine studies.
Date: October 25, 2007
Title: AIDS Vaccine May Raise Infection Risk: Researchers
Source: Reuters
Summary: More than 3,000 people who volunteered to receive an experimental Merck and Co. AIDS vaccine are being told to come back and get extra tests because the jab may itself raise the risk of infection. Researchers stress that they do not yet have enough information to say whether those who got the shot indeed are more susceptible to infection with HIV.
Date: October 25, 2007
Title: Warning Is Sent to AIDS Vaccine Volunteers
Source: The Washington Post
Summary: HIV/AIDS researchers in South Africa began warning 801 volunteers who participated in an HIV vaccine trial about a possible increased risk of HIV.
Date: October 6, 2007
Title: Try, try again
Source: The Philadelphia Inquirer
Summary: Lessons learned from the discontinued Step and Phambili trials.
Date: September 28, 2007
Title: Failed HIV vaccine study disappoints local participants
Source: Southern Voice
Summary: Interview with a vaccine trial volunteer in Atlanta. Scott Smith, 39, a volunteer for the vaccine research for just over two years said, "I was bummed. But I knew what the chances were." Smith will continue going to his scheduled appointments for however long researchers want to follow participants to find other useful information in the failed trial. "Every test helps us get closer to a vaccine," he said.
Date: September 22, 2007
Title: Failure of Vaccine Test Is Setback in AIDS Fight
Source: New York Times
Summary: The Step Study was closely watched because experts considered the vaccine one of most promising to be tested on people so far. This was also the first of a new class of H.I.V. vaccine to get this far in clinical trials. The failure of the vaccine raises questions about whether the new approach will work.
Date: September 21, 2007
Title: AVAC voices disappointment in trial result
Source: AVAC
Summary: Executive Director Mitchell Warren of the AIDS Vaccine Advocacy Coalition comments on the discontinuation of the Step Study.
Date: September 11, 2007
Title: South Africa: Vaccine trial volunteers contributing to AIDS fight
Source: Reuters
Summary: Several volunteers in HVTN's Phambili trial speak about their participation in helping to fight AIDS.
Date: September 6, 2007
Title: Scripps Research scientists shed new light on how antibodies fight HIVs
Source: EurekAlert
Summary: Results from a study looking at how protection against HIV occurs suggest the importance of antibody activity against both infected cells and free virus for effective protection. The study shows that protection against HIV was dependent upon the ability of antibodies to interact with immune cell Fc receptors. Fc receptors are found on the surface of immune cells, such as natural killer cells. The Fc receptor binds to the Fc region of an antibody after an antibody binds to a pathogen, targeting the pathogen for attack by the immune system.
Date: September 6, 2007
Title: HIV/AIDS: Allied responses
Source: Nature
Summary: Scientific journal article cited in story above. The main function of neutralizing antibodies is to block viral entry into host cells. But, for maximal protection against HIV, such antibodies must call upon other elements of the immune system to help with the job.
Date: August 31, 2007
Title: SAfrica HIV vaccine results promising: researchers
Source: Reuters
Summary: Preliminary data from the HVTN 204 trial found that the majority of participants experienced a positive immune response. Gavin Churchyard, the study's principal investigator is interviewed.
Date: August 21, 2007
Title: The good news about AIDS vaccine research
Source: Seattle Times
Summary: Nearly 1,000 scientists from around the world who gathered for the AIDS Vaccine 2007 Conference have a lot to share, much of it good news. Optimism is high for good reason. Collaborative efforts, solidified by creation of the Global HIV/AIDS Vaccine Enterprise seven years ago, are yielding fruit. Thirty-three vaccine candidates are undergoing human trials on every continent.
Date: August 21, 2007
Title: In hunt for HIV vaccine, focus shifts to stopping transmission
Source: Seattle Times
Summary: Some researchers say the most realistic goal now isn't a vaccine to prevent HIV infection, but rather one that prevents HIV from being passed on.
Date: August 21, 2007
Title: Controlling AIDS lies in distant hope of vaccine: Researchers say 20 years of work was misfocused
Source: Seattle Post-Intelligencer
Summary: Today, more than 20 years after health officials predicted an HIV vaccine was just around the corner, many scientists admit they aren't certain they're even yet on the right street.
Date: August 20, 2007
Title: Julie McElrath on AIDS Vaccine 07
Source: KUOW radio
Summary: A major international AIDS vaccine conference kicks off today in Seattle. The annual event is considered the premier forum to share research on HIV vaccine development.
Date: July 25, 2007
Title: Charlie Rose Science: AIDS (video)
Source: Google Video
Summary: The seventh episode in the Charlie Rose Science series explores the global AIDS epidemic, including a discussion of prevention and treatment possibilities and the role of the world community in fighting the growing pandemic.
Date: July 11, 2007
Title: AIDS by the Numbers
Source: Scienceline
Summary: The effort to produce an AIDS vaccine is gathering steam, and Beryl Koblin of the New York Blood Center is at the forefront.
Date: May 19, 2007
Title: Reporting AIDS: HIV Vaccine Trials (video)
Source: Health Dot
Summary: Steven Chang, site coordinator at the New York City HIV Vaccine Trial Unit, and Legend Riviera, a trial volunteer, speak about HIV vaccines.
Date: May 6, 2007
Title: HIV: the final battle
Source: The Seattle Times
Summary: Dr. Julie McElrath, HVTN Director of Laboratories, discusses the various achievements made in HIV vaccine research, ten years after President Clinton first challenged the scientific community.
Date: Apr 13, 2007
Title: Mice new frontier in HIV study
Source: Dallas Voice
Summary: Dallas researchers make breakthrough in HIV research that could lead to major advances in prevention, treatment of virus.
Date: Mar 28, 2007
Title: Male circumcision prevents AIDS
Source: World Health Organization
Summary: WHO and UNAIDS announce recommendations from expert consultation on male circumcision for HIV prevention.
Date: Feb 8, 2007
Title: KUOW radio interviews Steve Wakefield
Source: KUOW radio
Summary: Black people make up 6.5 percent of the King County population. But Black people account for 22 percent of new HIV cases in King County. Public Health Seattle-King County says that number is unacceptable, and it's getting worse. That's why they hit the streets for National Black HIV/AIDS Awareness Day.

Older News